Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DA-5230 and DA-5230-R in healthy adults
NCT07513649Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Started May 2026; status: completed.
02
Drugs
dapagliflozin
Beyond the preview
Go deeper on NCT07513649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513649.